U.S. Markets close in 14 mins
  • S&P 500

    4,119.18
    -44.82 (-1.08%)
     
  • Dow 30

    33,947.49
    -209.20 (-0.61%)
     
  • Nasdaq

    11,919.23
    -194.56 (-1.61%)
     
  • Russell 2000

    1,943.70
    -28.91 (-1.47%)
     
  • Crude Oil

    78.46
    +1.32 (+1.71%)
     
  • Gold

    1,886.50
    +1.70 (+0.09%)
     
  • Silver

    22.30
    +0.12 (+0.55%)
     
  • dólar/euro

    1.0715
    -0.0016 (-0.1500%)
     
  • 10-Yr Bond

    3.6530
    -0.0210 (-0.57%)
     
  • Vix

    19.68
    +1.02 (+5.47%)
     
  • dólar/libra

    1.2066
    +0.0014 (+0.1170%)
     
  • yen/dólar

    131.4220
    +0.3500 (+0.2670%)
     
  • BTC-USD

    22,889.81
    -302.88 (-1.31%)
     
  • CMC Crypto 200

    527.17
    -9.73 (-1.81%)
     
  • FTSE 100

    7,885.17
    +20.46 (+0.26%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday June 14, 2022 at 10:00 a.m. P.T./ 1:00 p.m. E.T. The fireside chat will be held at the Terranea Resort, Rancho Palos Verdes, CA.

The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com